Advertisement

Mechanisms of Resistance by Gram-Positive Bacteria (Streptococci and Enterococci)

  • Javier Aspa Marco
  • Olga Rajas Naranjo
  • Felipe Rodriguez de Castro
  • Buenaventura Buendía
  • Jesús Sanz Sanz
Part of the Emerging Infectious Diseases of the 21st Century book series (EIDC)

Keywords

Streptococcus Pneumoniae Clin Infect Antimicrob Agent Pneumococcal Pneumonia Macrolide Resistance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Acar, J.F. and Buu-Hoi, A.Y., (1988), Resistance patterns of important gram-positive pathogens. J Antimicrob Chemother, 21 (Suppl. C), 41–47.PubMedGoogle Scholar
  2. Alfageme, I.; Aspa, J.; Bello, S.; Blanquer, J.; Blanquer, R.; Borderias, L.; Bravo, C.; de Celis, R.; de Gracia, X.; Dorca, J.; Gallardo, J.; Gallego, M.; Menendez, R.; Molinos, L.; Paredes, C.; Rajas, O.; Rello, J.; Rodriguez de Castro, F.; Roig, J.; Sanchez-Gascon, F.; Torres, A. and Zalacain, R., (2005), [Guidelines for the Diagnosis and Management of Community-Acquired Pneumonia. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR).]. Arch Bronconeumol, 41, 272–289.PubMedGoogle Scholar
  3. Allen, G.P.; Kaatz, G.W. and Rybak, M.K., (2003), Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. Antimicrob Agents Chemother, 47, 2606–2614.PubMedGoogle Scholar
  4. Ambrose, P.G.; Bhavnani, S.M. and Owes, R.C. Jr., (2003), Clinical pharmacodynamics of quinolones. Infect Dis Clin North Am, 17, 529–543.PubMedGoogle Scholar
  5. Appelbaum, P.C., (1992), Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis, 15, 77–83.PubMedGoogle Scholar
  6. Appelbaum, P.C., (2002), Resistance among Streptococcus pneumoniae: Implications for drug selection. Clin Infect Dis, 34, 1613–1620. a. (aldfkald)PubMedGoogle Scholar
  7. Appelbaum, P.C.; Bhamjee, A.; Scragg, J.N.; Hallett, A.F.; Bowen, A.J. and Cooper, R.C., (1977), Streptococcus pneumoniae resistant to penicillin and chloramphenicol. Lancet, 2, 995–997.PubMedGoogle Scholar
  8. Aspa, J.; Rajas, O.; Rodriguez de Castro, F.; Blanquer, J.; Zalacain, R.; Fenoll, A.; de Celis, R.; Vargas, A.; Rodriguez Salvanes, F.; Espana, P.P.; Rello, J. and Torres, A., (2004), Drug-resistant pneumococcal pneumonia: clinical relevance and related factors. Clin Infect Dis, 38, 787–798.PubMedGoogle Scholar
  9. Aspa, J., Rajas, O., Rodriguez de Castro, F., Huertas, C., Borderías, L., F.J., C., Tábara, J., Hernández-Flix, S., Martínez-Sanchis, A. and Torres, A., (2006), Impact of Initial antibiotic choice on mortality from pneumococcal pneumonia. Eur Respir J, 27, 1–10.Google Scholar
  10. Austrian, R. and Gold, J., (1964), Pneumococcal bacteremia with special reference to bacteremic pneumococcal pneumonia. Ann Intern Med, 60, 759–776.PubMedGoogle Scholar
  11. Baddour, L.M., Yu, V.L., Klugman, K.P., Feldman, C., Ortqvist, A., Rello, J., Morris, A.J., Luna, C., Snydman, D.R., Ko, W.C., Chedid, M.B., Hui, D.S., Andremont, A., Chiou, C.C., International Pneumococcal Study Group, (2004), Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med, 170, 440–444.PubMedGoogle Scholar
  12. Ball, P., Baquero, F., Cars, O., File, T., Garau, J., Klugman, K., Low, D.E., Rubinstein, E. and Wise, R., (2002), Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother, 49, 31–40.PubMedGoogle Scholar
  13. Baquero, F., (2001), Low-level antibacterial resistance: a gateway to clinical resistance. Drug Resist Updat, 4, 93–105.PubMedGoogle Scholar
  14. Baquero, F., Barrett, J.F., Courvalin, P., Morrissey, I., Piddock, L. and Novick, W.J., (1998a), Epidemiology and mechanisms of resistance among respiratory tract pathogens. Clin Microbiol Infect, 4 (Suppl. 2), S19–S26.Google Scholar
  15. Baquero, F., Blazquez, J., Loza, E. and Canton, R., (1998b), Molecular basis of resistance to beta-lactams in infections by Streptococcus pneumoniae. Med Clin (Barc), 110 (Suppl. 1), 8–11.Google Scholar
  16. Baquero, F., García-Rodriguez, J.A., Garcia de Lomas, J. and Aguilar, L., (1999), Antimicrobial resistance of 1,113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: results of a 1-year (1996–1997) multicenter surveillance study. The Spanish Surveillance Group for Respiratory Pathogens. Antimicrob Agents Chemother, 43, 357–359.PubMedGoogle Scholar
  17. Barnett, E.D. and Klein, J.O., (1995), The problem of resistant bacteria for the management of acute otitis media. Pediatr Clin North Am, 42, 509–517.PubMedGoogle Scholar
  18. Bast, D., Low, D., Duncan, C., Kilburn, L., Mandell, L., Davidson, R. and de Azavedo, J., (2000), Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efllux to levels of resistance. Antimicrob Agents Chemother, 44, 3049–3054.PubMedGoogle Scholar
  19. Bauer, T., Ewig, S., Marcos, M.A., Schultze-Werninghaus, G. and Torres, A., (2001), Streptococcus pneumoniae in community-acquired pneumonia. How important is drug resistance? Med Clin North Am, 85, 1367–1379.PubMedGoogle Scholar
  20. Bedos, J.P., Chevret, S., Chastang, C., Geslin, P. and Regnier, B., (1996), Epidemiological features of and risk factors for infection by Streptococcus pneumoniae strains with diminished susceptibility to penicillin: findings of a French survey. Clin Infect Dis, 22, 63–72.PubMedGoogle Scholar
  21. Berry, V., Page, R., Satterfield, J., Singley, C., Straub, R. and Woodnutt, G., (2000), Comparative in vivo activity of gemifloxacin in a rat model of respiratory tract infections. J Antimicrob Chem, 45 (S1), 79–85.Google Scholar
  22. Bhavnani, S.M., Hammel, J., Jones, R., Ambrose, P., (2005). Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States. Diag Microbiol Infect Dis, 51, 31–37.Google Scholar
  23. Blondeau, J.M., Zhao, X., Hansen G., Drlica, K., (2001), Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother, 45, 433–438.PubMedGoogle Scholar
  24. Bonnefoy, A., Girard, A.M., Agouridas, C. and Chantot, J.F., (1997), Ketolides lack inducibility properties of MLS(B) resistance phenotype. J Antimicrob Chemother, 40, 85–90.PubMedGoogle Scholar
  25. Boswell, F.J., Andrews, J.M., Ashby, J.P., Fogarty, C., Brenwald, N.P. and Wise, R., (1998), The in-vitro activity of HMR 3647, a new ketolide antimicrobial agent. J Antimicrob Chemother, 42, 703–709.PubMedGoogle Scholar
  26. Bozdogan, B. and Appelbaum, P.C., (2004), Oxazolidinones: activity, mode of action, and mechanism of resistance. Int J Antimicrob Agents, 23, 113–119.PubMedGoogle Scholar
  27. Bozdogan, B., Esel, D., Whitener, C., Browne, F.A. and Appelbaum, P.C., (2003), Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J Antimicrob Chemother, 52, 864–868PubMedGoogle Scholar
  28. Breiman, R.F., Butler, J.C., Tenover, F.C., Elliott, J.A. and Facklam, R.R., (1994), Emergence of drug-resistant pneumococcal infections in the United States. JAMA, 271, 1831–1835.PubMedGoogle Scholar
  29. Brown, R.B., Iannini, P., Gross, P. and Kunkel, M., (2003), Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Chest, 123, 1503–1511.PubMedGoogle Scholar
  30. Brueggemann, A.B., Coffman, S.L., Rhomberg, P., Huynh, H., Almer, L., Nilius, A., Flamm, R. and Doern, G.V., (2002), Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994–1995. Antimicrob Agents Chemother, 46,680–688.Google Scholar
  31. Buckingham, S.C., Brown, S.P. and Joaquin, V.H., (1998), Breakthrough bacteremia and meningitis during treatment with cephalosporins parenterally for pneumococcal pneumonia. J Pediatr, 132, 174–176.PubMedGoogle Scholar
  32. Burdett, V., (1991), Purification and characterization of Tet(M), a protein that renders ribosomes resistant to tetracycline. J Biol Chem, 266, 2872–2877.PubMedGoogle Scholar
  33. Burgess, D.S., (1999), Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance. Chest, 115, 19S-23S.PubMedGoogle Scholar
  34. Burgess, D.S., Lewis, J.S., 2nd., (2000), Effect of macrolides as part of initial empiric therapy on medical outcomes for hospitalized patients with community-acquired pneumonia. Clin Ther, 22,872–878.PubMedGoogle Scholar
  35. Burleson, B.S., Ritchie, D.J., Micek, S.T. and Dunne, W.M., (2004), Enterococcus faecalis resistant to linezolid: case series and review of the literature. Pharmacotherapy, 24, 1225–1231.PubMedGoogle Scholar
  36. Butler, J.C., Hofmann, J., Cetron, M.S., Elliott, J.A., Facklam, R.R. and Breiman, R.F., (1996), The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention’s Pneumococcal Sentinel Surveillance System. J Infect Dis, 174, 986–993.PubMedGoogle Scholar
  37. Campbell, G.D., Jr and Silberman, R., (1998), Drug-resistant Streptococcus pneumoniae. Clin Infect Dis, 26, 1188–1195.PubMedGoogle Scholar
  38. Catalan, M.J., Fernandez, J.M., Vazquez, A., Varela de Seijas, E., Suarez, A. and Bernaldo de Quiros, J.C., (1994), Failure of cefotaxime in the treatment of meningitis due to relatively resistant Streptococcus pneumoniae. Clin Infect Dis, 18, 766–769.PubMedGoogle Scholar
  39. Cercenado, E., Garcia-Garrote, F. and Bouza, E., (2001), In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates. J Antimicrob Chemother, 47, 77–81.PubMedGoogle Scholar
  40. Cerda Zolezzi, P., Laplana, L. M., Calvo, C.R., Cepero, P.G., Erazo, M.C. and Gòmez-Lus, R., (2004), Molecular basis of resistance to macrolides and other antibiotics in commensal viridans group streptococci and Gemela spp. and transfer of resistance genes to Streptococcus pneumoniae. Antimicrob Agents Chemother, 48, 3462–3467.Google Scholar
  41. Chabbert, Y.A., (1956), Antagonisme in vitro entre lérythromycine et la spiramycine. Ann Inst Pasteur (Paris), 90, 787–790.Google Scholar
  42. Chabbert, Y.A. and Courvalin, P., (1971), Synergism of antibiotic components of the streptogramin group. Pathol Biol (Paris), 19, 613–619.Google Scholar
  43. Chen, D.K., McGeer, A., de Azavedo, J.C. and Low, D.E., (1999), Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med, 341, 233–239.PubMedGoogle Scholar
  44. Chenoweth, C.E., Saint, S., Martinez, F., Lynch, J.P., 3rd and Fendrick, A.M., (2000), Antimicrobial resistance in Streptococcus pneumoniae: implications for patients with community-acquired pneumonia. Mayo Clin Proc, 75, 1161–1168.PubMedGoogle Scholar
  45. Choi, E.H. and Lee, H.J., (1998), Clinical outcome of invasive infections by penicillin-resistant Streptococcus pneumoniae in Korean children. Clin Infect Dis, 26, 1346–1354.PubMedGoogle Scholar
  46. Chow, J.W., Donahedian, S.M. and Zervos, M.J., (1997), Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia. Clin Infect Dis, 24, 90–91.PubMedGoogle Scholar
  47. Clavo-Sanchez, A.J., Giron-Gonzalez, J.A., Lopez-Prieto, D., Canueto-Quintero, J., Sanchez-Porto, A., Vergara-Campos, A., Marin-Casanova, P. and Cordoba-Dona, J.A., (1997), Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: a multicenter study. Clin Infect Dis, 24, 1052–1059.PubMedGoogle Scholar
  48. Clay, K.D., Hanson, J.S., Pope, S.D., Rissmiller, R.W., Purdum, P.P., 3rd & Banks, P.M., (2006), Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern Med, 144, 415–420.PubMedGoogle Scholar
  49. Coburn, A.F., (1949), The epidemiology of haemolytic Streptococcus during World War in the United States Navy. Williams & Williams, Baltimore.Google Scholar
  50. Colca, J.R., McDonald, W.G., Waldon, D.J., Thomasco, L.M., Gadwood, R.C., Lund, E.T., Cavey, G.S., Mathews, W.R., Adams, L.D., Cecil, E.T., Pearson, J.D., Bock, J.H., Mott, J.E., Shinabarger, D.L., Xiong, L. and Mankin, A.S., (2003), Cross-linking in the living cell locates the site of action of oxazolidinone antibiotics. J Biol Chem, 278, 21972–21979.PubMedGoogle Scholar
  51. Cornaglia, G., Hryniewicz, W., Jarlier, V., Kahlmeter, G., Mittermayer, H., Stratchounski, L. and Baquero, F., (2004), European recommendations for antimicrobial resistance surveillance. Clin Microbiol Infect, 10, 349–383.PubMedGoogle Scholar
  52. Craig, W.A., (1998a), Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis, 26, 1–10; quiz 11–12.Google Scholar
  53. Craig, W.A., (1998b), Choosing an antibiotic on the basis of pharmacodynamics. Ear Nose Throat J, 77, 7–12.Google Scholar
  54. Critchley, I.A., Blosser-Middleton, R.S., Jones, M.E., Karlowsky, J.A., Karginova, E.A., Thornsberry, C. and Sahm, D.F., (2002), Phenotypic and genotypic analysis of levofloxacin-resistant clinical isolates of Streptococcus pneumoniae collected in 13 countries during 1999–2000. Intern J Antimicrob Agents, 20, 100–107.Google Scholar
  55. Dalhoff, A., Krasemann, C., Begener, S. and Tillotson, G., (2001), Penicillin-resistant Streptococcus pneumoniae: review of moxifloxacin activity. Clin Infect Dis, 32, S22–S29.PubMedGoogle Scholar
  56. Davidson, R., Cavalcanti, R., Brunton, J.L., Bast, D.J., de Azavedo, J.C., Kibsey, P., Fleming, C. and Low, D.E., (2002), Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med, 346, 747–750.PubMedGoogle Scholar
  57. Davies, T., Goering, R.V., Lovgren, M., Talbot, J.A., Jacobs, M.R. and Appelbaum, P.C., (1999), Molecular epidemiological survey of penicillin-resistant Streptococcus pneumoniae from Asia, Europe, and North America. Diagn Microbiol Infect Dis, 34, 7–12.PubMedGoogle Scholar
  58. Davies, T.A., Evangelista, A., Pfleger, S., Bush, K., Sahm, D.F. and Goldschmidt, R., (2002), Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical strains of Streptococcus pneumoniae isolated in the United States in 1992 to 1996 and 1999 to 2000. Antimicrob Agents Chemother, 46, 119–124.PubMedGoogle Scholar
  59. De la Campa, A.G., Balsalobre, I., Ardanuy, C., Fenoll, A. Perez-Trallero, E. and Liñares, J., (2004), Fluoroquinolone resistance in penicillin-resistant Streptococcus pneumoniae clones, Spain. Emerg Infect Dis, 10, 1751–1759.PubMedGoogle Scholar
  60. Deeks, S.L., Palacio, R., Ruvinsky, R., Kertesz, D.A., Hortal, M., Rossi, A., Spika, J.S. and Di Fabio, J.L., (1999), Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae. The Streptococcus pneumoniae Working Group. Pediatrics, 103, 409–413.PubMedGoogle Scholar
  61. Dever, L.L., Smith, S.M., Handwerger, S. and Eng, R.H., (1995), Vancomycin-dependent Enterococcus faecium isolated from stool following oral vancomycin therapy. J Clin Microbiol, 33, 2770–2773.PubMedGoogle Scholar
  62. Doern, G.V., (2001), Antimicrobial resistance with Streptococcus pneumoniae: much ado about nothing? Semin Respir Infect, 16, 177–185.PubMedGoogle Scholar
  63. Doern, G.V., Pfaller, M.A., Kugler, K., Freeman, J. and Jones, R.N., (1998), Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Clin Infect Dis, 27, 764–770.PubMedGoogle Scholar
  64. Doern, G.V., Richter, S.S., Miller, A., Miller, N., Rice, C., Heilmann, K. and Beekmann, S., (2005), Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? Clin Infect Dis, 41, 139–148.PubMedGoogle Scholar
  65. Dong, Y., Zhao, X., Domagala, J., and Drlica, K., (1999), Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob. Agents Chemother. 43: 1756–1758.PubMedGoogle Scholar
  66. Dowell, S.F., Smith, T., Leversedge, K. and Snitzer, J., (1999), Failure of treatment of pneumonia associated with highly resistant pneumococci in a child. Clin Infect Dis, 29, 462–463.PubMedGoogle Scholar
  67. Dowzicky, M., Talbot, G.H., Feger, C., Prokocimer, P., Etienne, J. and Leclercq, R., (2000), Characterization of isolates associated with emerging resistance to quinupristin/dalfopristin (Synercid) during a worldwide clinical program. Diagn Microbiol Infect Dis, 37, 57–62.PubMedGoogle Scholar
  68. Drlica, K. and Zhao, X., (1997), DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev, 61, 377–392.PubMedGoogle Scholar
  69. Ekdahl, K., Ahlinder, I., Hansson, H.B., Melander, E., Molstad, S., Soderstrom, M. and Perssons, K., (1997), Duration of nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae: experiences from the South Swedish Pneumococcal Intervention Project. Clin Infect Dis, 25, 1113–1117.PubMedGoogle Scholar
  70. Endimiani, A., Brigante, G., Bettaccini, A., Luzzaro, F., Grossi, P., Toniolo, A.Q., (2005), Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia. BMC Infect Dis, 5, 106–109.PubMedGoogle Scholar
  71. Empey, P.E., Jennings, H.R., Thornton, A.C., Rapp, R.P. and Evans, M.E., (2001), Levofloxacin failure in a patient with pneumococcal pneumonia. Ann Pharmacother, 35, 687–690.PubMedGoogle Scholar
  72. Eriksen, K., (1945), Studies on induced resistance to penicillin in a Pneumococcus type 1. Act Pathol Microbiol Scan, 22, 398–405.Google Scholar
  73. Ewig, S., Ruiz, M., Torres, A., Marco, F., Martinez, J.A., Sanchez, M. and Mensa, J., (1999), Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae. Am J Respir Crit Care Med, 159, 1835–1842.PubMedGoogle Scholar
  74. Feikin, D.R., Dowell, S.F., Nwanyanwu, O.C., Klugman, K.P., Kazembe, P.N., Barat, L.M., Graf, C., Bloland, P.B., Ziba, C., Huebner, R.E. and Schwartz, B., (2000a), Increased carriage of trimethoprim/sulfamethoxazole-resistant Streptococcus pneumoniae in Malawian children after treatment for malaria with sulfadoxine/pyrimethamine. J Infect Dis, 181, 1501–1505.Google Scholar
  75. Feikin, D.R., Schuchat, A., Kolczak, M., Barrett, N.L., Harrison, L.H., Lefkowitz, L., McGeer, A., Farley, M.M., Vugia, D.J., Lexau, C., Stefonek, K.R., Patterson, J.E. and Jorgensen, J.H., (2000b), Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995–1997. Am J Public Health, 90, 223–229.Google Scholar
  76. Feldman, C., (2004), Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia. J Lab Clin Med, 143, 269–283.PubMedGoogle Scholar
  77. Felmingham, D. and Gruneberg, R.N., (2000), The Alexander Project 1996–1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother, 45, 191–203.PubMedGoogle Scholar
  78. Fenoll, A., Asensio, G., Jado, I., Berron, S., Camacho, M.T., Ortega, M. and Casal, J., (2002), Antimicrobial susceptibility and pneumococcal serotypes. J Antimicrob Chemother, 50 (Suppl. 2), 13–19.PubMedGoogle Scholar
  79. Fenoll, A., Jado, I., Vicioso, D., Perez, A. and Casal, J., (1998), Evolution of Streptococcus pneumoniae serotypes and antibiotic resistance in Spain: update (1990 to 1996). J Clin Microbiol, 36, 3447–3454.PubMedGoogle Scholar
  80. Fenoll, A., Martin Bourgon, C., Munoz, R., Vicioso, D. and Casal, J., (1991), Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing systemic infections in Spain, 1979–1989. Rev Infect Dis, 13, 56–60.PubMedGoogle Scholar
  81. Fernandez-Moreira, E., Balas, D., Gonzalez, I. and De la Campa, A.G., (2000), Fluoroquinolones inhibit preferentially Streptococcus pneumoniae DNA topoisomerase IV than DNA gyrase native proteins. Microb Drug Resist, 6, 259–267.PubMedGoogle Scholar
  82. File, T.M. and Tillotson, G.S., (2004), Gemifloxacin: a new, potent fluoroquinolone for the therapy of lower respiratory tract infections. Expert Ref Anti Infect Ther, 2(6), 831–843.Google Scholar
  83. Fine, M.J., Auble, T.E., Yealy, D.M., Hanusa, B.H., Weissfeld, L.A., Singer, D.E., Coley, C.M., Marrie, T.J. and Kapoor, W.N., (1997), A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med, 336, 243–250.PubMedGoogle Scholar
  84. Finland M., (1955), Changing patterns of resistance of certain common pathogenic bacteria to antimicrobial agents. N Engl J Med, 252:570–80.PubMedGoogle Scholar
  85. Finland, M., (1971), Increased resistance in the pneumococcus. N Engl J Med, 284, 212–214.PubMedGoogle Scholar
  86. Finland, M., Jones, W.F., Jr. and Nichols, R.L., (1956), Development of resistance and cross-resistance in vitro to erythromycin, carbomycin, spiramycin, oleandomycin and streptogramin. Proc Soc Exp Biol Med, 93, 388–393.PubMedGoogle Scholar
  87. Fleming, A., (1929), On the antibacterial action of culture of a Penicillium, with special reference to their use in isolation of H. influenzae. Br J Exp Pathol, 10, 226–236.Google Scholar
  88. Florey, M.E., (1943), General and local administration of penicillin. Lancet, 1, 387–397.Google Scholar
  89. Fogarty, C., Goldschmidt, R. and Bush, K., (2000), Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin. Clin Infect Dis, 31, 613–615.PubMedGoogle Scholar
  90. Fraimow, H., Knob, C., Herrero, I. and, Patel, R., (2005), Putative VanRS-like two component regulatory system associated with the inducible glycopeptide resistance cluster of Paenibacillus popilliae. Antimicrob Agents Chemother, 49, 2625–2633.PubMedGoogle Scholar
  91. Friedland, I.R., (1995), Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease. Pediatr Infect Dis J, 14, 885–890.PubMedGoogle Scholar
  92. Friedland, I.R. and McCracken, G.H., Jr., (1994), Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med, 331, 377–382.PubMedGoogle Scholar
  93. Fukuda, H. and Hiramatsu, K., (1999), Primary Targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrob Agents Chemother, 43, 410–412.PubMedGoogle Scholar
  94. Fuller, J.D. and Low, D.E., (2005), A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolones-resistance. Clin Infect Dis, 41, 118–121.PubMedGoogle Scholar
  95. Fung, H.B., Kirschenbaum, H.L. and Ojofeitimi, B.O., (2001), Linezolid: an oxazolidinone antimicrobial agent. Clin Ther, 23, 356–391.PubMedGoogle Scholar
  96. Garau, J., (2002), Treatment of drug-resistant pneumococcal pneumonia. Lancet Infect Dis, 2, 404–415.PubMedGoogle Scholar
  97. Garcia-Rey, C., Aquilar, L. and Baquero, F., (2000), Influences of different factors on prevalence of ciprofloxacin resistance in Streptococcus pneumoniae in Spain. Antimicrob Agents Chemother, 44, 3481–3482.PubMedGoogle Scholar
  98. Garrod, L.P., (1957), The erythromycin group of antibiotics. Br Med J, 13, 57–63.Google Scholar
  99. Gay, K., Baughman, W., Miller, Y., Jackson, D., Whitney, C., Schuchat, A., Farley, M., Tenover, F. and Stephens, D., (2000), The emergence of Streptococcus pneumoniae resistant to macrolide antimicrobial agents: a 6-year population-based assessment. J Infect Dis, 182, 1417–1424.PubMedGoogle Scholar
  100. Gillespie, S.H., Voelker, L.L., Ambler, J.E., Traini. C. and Dickens, A., (2003), Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation. Microb Drug Resist, 9, 17–24.PubMedGoogle Scholar
  101. Gilmore, M.S., Behnke, D. and Ferreti, J.J., (1982), Evolutionary relatedness of MLS resistance and replication function sequences on streptococcal antibiotic resistance plasmids. In D. Schlessinger, editor, Microbiology-1992. Washington DC, pp. 174–176.Google Scholar
  102. Graham, D.J., (2006), Telithromycin and acute liver failure. N Engl J Med, 355, 2260–2261.PubMedGoogle Scholar
  103. Hamilton-Miller, J.M., (2002), Vancomycin-resistant Staphylococcus aureus: a real and present danger? Infection, 30, 118–124.PubMedGoogle Scholar
  104. Hancock, R.E., (2005), Mechanisms of action of newer antibiotics for Gram-positive pathogens. Lancet Infect Dis, 5, 209–218.PubMedGoogle Scholar
  105. Hansman, D. and Bullen, M.M., (1967), A resistant pneumococcus (letter). Lancet, 2, 264–265.Google Scholar
  106. Hansman, D., Glasgow, H.N., Sturt, J., Devitt, L. and Douglas, R., (1971a), Increased resistance to penicillin of pneumococci isolated from man. N Engl J Med, 284, 175–177.Google Scholar
  107. Hansman, D., Glasgow, H.N., Sturt, J., Devitt, L. and Douglas, R.M., (1971b), Pneumococci insensitive to penicillin. Nature, 230, 407–408.Google Scholar
  108. Heffelfinger, J.D., Dowell, S.F., Jorgensen, J.H., Klugman, K.P., Mabry, L.R., Musher, D.M., Plouffe, J.F., Rakowsky, A., Schuchat, A. and Whitney, C.G., (2000), Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med, 160, 1399–1408.PubMedGoogle Scholar
  109. Hershberger, E., Donabedian, S., Konstantinou, K. and Zervos, M.J., (2004), Quinupristin-dalfopristin resistance in gram-positive bacteria: mechanism of resistance and epidemiology. Clin Infect Dis, 38, 92–98.PubMedGoogle Scholar
  110. Hiramatsu, K., Hanaki, H., Ino, T., Yabuta, K., Oguri, T. and Tenover, F.C., (1997), Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother, 40, 135–136.PubMedGoogle Scholar
  111. Hiramatsu, K., Okuma, K., Ma, X.X., Yamamoto, M., Hori, S. and Kapi, M., (2002), New trends in Staphylococcus aureus infections: gycopeptide resistance in hospital and methicillin resistance in the community. Curr Opin Infect Dis, 15, 407–413.PubMedGoogle Scholar
  112. Ho, P.L., Tse, W.S., Tsang, K.W., Kwok, T.K., Ng, T.K., Cheng, V.C. and Chan, R.M., (2001), Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin Infect Dis, 32, 701–707.PubMedGoogle Scholar
  113. Hoban, D.J., Doern, G.V., Fluit, A.C., Roussel-Delvallez, M. and Jones, R.N., (2001), Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997–1999. Clin Infect Dis, 32 (Suppl. 2), S81–S93.PubMedGoogle Scholar
  114. Hofmann, J., Cetron, M.S., Farley, M.M., Baughman, W.S., Facklam, R.R., Elliott, J.A., Deaver, K.A. and Breiman, R.F., (1995), The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med, 333, 481–486.PubMedGoogle Scholar
  115. Hooper, D.C. and Wolfson, J.S., (1993), Quinolone Antimicrobial Agents. American Society for Microbiology, Washington.Google Scholar
  116. Hyde, T.B., Gay, K., Stephens, D.S., Vugia, D.J., Pass, M., Johnson, S., Barrett, N.L., Schaffner, W., Cieslak, P.R., Maupin, P.S., Zell, E.R., Jorgensen, J.H., Facklam, R.R. and Whitney, C.G., (2001), Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA, 286, 1857–1862.PubMedGoogle Scholar
  117. Jacobs, M.R., (1996), Increasing importance of antibiotic-resistant Streptococcus pneumoniae in acute otitis media. Pediatr Infect Dis J, 15, 940–943.PubMedGoogle Scholar
  118. Jacobs, M.R., Koornhof, H.J., Robins-Browne, R.M., Stevenson, C.M., Vermaak, Z.A., Freiman, I., Miller, G.B., Witcomb, M.A., Isaacson, M., Ward, J.I. and Austrian, R., (1978), Emergence of multiply resistant pneumococci. N Engl J Med, 299, 735–740.PubMedGoogle Scholar
  119. Jacoby, G.A., (1994), Prevalence and resistance mechanisms of common bacterial respiratory pathogens. Clin Infect Dis, 18, 951–957.PubMedGoogle Scholar
  120. Janoir, C., Zeller, V., Kitzis, M.D., Moreau, N.J. and Gutmann, L., (1996), High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob Agents Chemother, 40, 2760–2764.PubMedGoogle Scholar
  121. Johansen, H.K., Jensen, T.G., Dessau, R.B., Lundgren, B. and Frimodt-Moller, N., (2000), Antagonism between penicillin and erythromycin against Streptococcus pneumoniae in vitro and in vivo. J Antimicrob Chemother, 46, 973–980.PubMedGoogle Scholar
  122. Johnston, N.J., De Azavedo, J.C., Kellner, J.D. and Low, D.E., (1998), Prevalence and characterization of the mechanisms of macrolide, lincosamide, and streptogramin resistance in isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother, 42, 2425–2426.PubMedGoogle Scholar
  123. Jones, R.N., (1999), The impact of antimicrobial resistance: changing epidemiology of community-acquired respiratory-tract infections. Am J Health Syst Pharm, 56, S4–S11.PubMedGoogle Scholar
  124. Jones, R.N., Farrell, D.J. and Morrissey, I., (2003), Quinupristin-dalfopristin resistance in Streptococcus pneumoniae: novel L22 ribosomal protein mutation in two clinical isolates from the SENTRY antimicrobial surveillance program. Antimicrob Agents Chemother, 47, 2696–2698.PubMedGoogle Scholar
  125. Jordan, D.C. and Inniss, W.E., (1959) Selective inhibition of ribonucleic acid synthesis in Staphylococcus aureus by vancomycin. Nature, 184, 1984–1985.Google Scholar
  126. Jordan, D.C. and Mallory H.D., (1964), Site of action of vancomycin on Staphylococcus aureus. Antimicrob Agents Chemother, 10, 489–494.PubMedGoogle Scholar
  127. Jorgensen, J.H., Crawford, S.A., Kelly, C.C. and Patterson, J.E., (2003), In vitro activity of daptomycin against vancomycin-resistant enterococci of various Van types and comparison of susceptibility testing methods. Antimicrob Agents Chemother, 47, 3760–3763.PubMedGoogle Scholar
  128. Kaplan, S.L. and Mason, E.O., Jr., (1998), Management of infections due to antibiotic-resistant Streptococcus pneumoniae. Clin Microbiol Rev, 11, 628–644.PubMedGoogle Scholar
  129. Karchmer, A.W., (2004), Increased antibiotic resistance in respiratory tract pathogens: PROTEKT US-an update. Clin Infect Dis, 39 (Suppl. 3), S142–S150.PubMedGoogle Scholar
  130. Karlowsky, J.A., Thornsberry, C., Jones, M.E., Evangelista, A.T., Critchley, I.A. and Sahm, D.F., (2003), Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998–2002). Clin Infect Dis, 36, 963–970.PubMedGoogle Scholar
  131. Kehoe, L.E., Snidwongse, J., Courvalin, P., Rafferty, J.B. and Murray, I.A., (2003), Structural basis of Synercid (quinupristin-dalfopristin) resistance in Gram-positive bacterial pathogens. J Biol Chem, 278, 29963–29970.PubMedGoogle Scholar
  132. Kelley, M.A., Weber, D.J., Gilligan, P. & Cohen, M.S., (2000), Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis, 31, 1008–1011.PubMedGoogle Scholar
  133. Kelly, L.J., (2001), Multidrug-resistant pneumococci isolated in the US: 1997–2001 TRUST surveillance (abstract). In: Program and abstrats of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago) (ASM), p.142,Washington DC.Google Scholar
  134. Kern, W.V., (2006), Daptomycin: first in a new class of antibiotics for complicated skin and soft-tissue infections. Int J Clin Pract, 60, 370–378PubMedGoogle Scholar
  135. Kislak, J.W., Razavi, L.M., Daly, A.K. and Finland, M., (1965), Susceptibility of pneumococci to nine antibiotics. Am J Med Sci, 250, 261–268.PubMedGoogle Scholar
  136. Klugman, K.P., (1990), Pneumococcal resistance to antibiotics. Clin Microbiol Rev, 3, 171–196.PubMedGoogle Scholar
  137. Klugman, K.P., (2002), Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections. Eur Respir J, 20 (Suppl. 36), 3S–8S.Google Scholar
  138. Klugman, K.P., (2004), Vaccination: a novel approach to reduce antibiotic resistance. Clin Infect Dis, 39, 649–651.PubMedGoogle Scholar
  139. Kramer, M.R., Rudensky, B., Hadas-Halperin, I., Isacsohn, M. and Melzer, E., (1987), Pneumococcal bacteremia–no change in mortality in 30 years: analysis of 104 cases and review of the literature. Isr J Med Sci, 23, 174–180.PubMedGoogle Scholar
  140. Leclercq, R. and Courvalin, P., (1991), Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification. Antimicrob Agents Chemother, 35, 1267–1272.PubMedGoogle Scholar
  141. Leclercq, R., Derlot, E., Duval, J. and Courvalin, P., (1988), Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med, 319, 157–161.PubMedGoogle Scholar
  142. Lewis, J.S., 2nd, Owens, A., Cadena, J., Sabol, K., Patterson, J.E. and Jorgensen, J.H., (2005), Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother, 49, 1664–1665.PubMedGoogle Scholar
  143. Li, X, Zhao, X., and Drlica, K., (2002), Selection of Streptococcus pneumoniae mutants having reduced susceptibility to levofloxacin and moxifloxacin. Antimicrob. Agents Chemother. 46: 522–524.PubMedGoogle Scholar
  144. Lim, S., Bast, D., McGeer, A., de Azavedo, J., Low, D.E., (2003), Antimicrobial susceptibility breakpoints and first-step parC putations in Streptococcus pneumoniae: redefining fluoroquinolone resistance. Emerg Infect Dis, 9, 833–837.PubMedGoogle Scholar
  145. Linares, J., De la Campa, A.G. and Pallares, R., (1999), Fluoroquinolone resistance in Streptococcus pneumoniae. N Engl J Med, 341, 1546–1547; author reply 1547–1548.PubMedGoogle Scholar
  146. Linares, J., Pallares, R., Alonso, T., Perez, J.L., Ayats, J., Gudiol, F., Viladrich, P.F. and Martin, R., (1992), Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979–1990). Clin Infect Dis, 15, 99–105.PubMedGoogle Scholar
  147. Lonks, J.R., Garau, J., Gomez, L., Xercavins, M., Ochoa de Echaguen, A., Gareen, I.F., Reiss, P.T. and Medeiros, A.A., (2002), Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis, 35, 556–564.PubMedGoogle Scholar
  148. Low, D.E., (2004), Quinolone resistance among pneumococci therapeutic and diagnostic implications. Clin Infect Dis, 38, S357–S362.PubMedGoogle Scholar
  149. Low, D.E., (2005), Fluoroquinolone-resistant pneumococci: maybe resistance isn’t futile?. Clin Infect Dis, 40, 236–238.PubMedGoogle Scholar
  150. Low, D.E., de Azavedo, J., Weiss, K., Mazzulli, T., Kuhn, M., Church, D., Forward, K., Zhanel, G., Simor, A. and McGeer, A., (2002), Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrob Agents Chemother, 46, 1295–1301.PubMedGoogle Scholar
  151. Lujan, M., Gallego, M., Fontanals, D., Mariscal, D. and Rello, J., (2004), Prospective observational study of bacteremic pneumococcal pneumonia: Effect of discordant therapy on mortality. Crit Care Med, 32, 625–631.PubMedGoogle Scholar
  152. Lynch, I.J. and Martinez, F.J., (2002), Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia. Clin Infect Dis, 34 (Suppl. 1), S27–S46.Google Scholar
  153. Lynch, III. J. and Zhanel, G., (2005), Escalation of antimicrobial resistance among Streptococcus pneumoniae: Implications for therapy. Sem Respir Crit Care Med, 26, 575–616.Google Scholar
  154. Maclean, I.H. and Fleming, A., (1939), M & B 639 and pneumococci. Lancet, 1, 562–568.Google Scholar
  155. Mandell, L.A., Wunderink, R.G., Anzueto, A., Bartlett, J.G., Campbell, G.D., Dean, N.C., Dowell, S.F., File, T.M., Jr., Musher, D.M., Niederman, M.S., Torres, A. and Whitney, C.G., (2007), Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis, 44 Suppl. (2), S27–72.PubMedGoogle Scholar
  156. Markiewicz, Z. and Tomasz, A., (1989), Variation in penicillin-binding protein patterns of penicillin-resistant clinical isolates of pneumococci. J Clin Microbiol, 27, 405–410.PubMedGoogle Scholar
  157. Marston, B.J., Plouffe, J.F., File, T.M., Jr, Hackman, B.A., Salstrom, S.J., Lipman, H.B., Kolczak, M.S. and Breiman, R.F., (1997), Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med, 157, 1709–1718.PubMedGoogle Scholar
  158. Martínez-Beltrán, J.C., (1994), Mecanismos de resistencia a los antimicrobianos en Gram-positivos. Rev Clin Esp, 803–813.Google Scholar
  159. Martinez, J.A., Horcajada, J.P., Almela, M., Marco, F., Soriano, A., Garcia, E., Marco, M.A., Torres, A. and Mensa, J., (2003), Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis, 36, 389–395.PubMedGoogle Scholar
  160. McCullers, J.A., English, B.K. and Novak, R., (2000), Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae from the cerebrospinal fluid of a patient who developed recrudescent meningitis. J Infect Dis, 181, 369–373.PubMedGoogle Scholar
  161. McDougal, L.K., Facklam, R., Reeves, M., Hunter, S., Swenson, J.M., Hill, B.C. and Tenover, F.C., (1992), Analysis of multiply antimicrobial-resistant isolates of Streptococcus pneumoniae from the United States. Antimicrob Agents Chemother, 36, 2176–2184.PubMedGoogle Scholar
  162. Menendez, R., Cordoba, J., Cuadra, P., Cremades, M., Lopez-Hontagas, J., Salavert, M., and Gobernado, M., (1999), Value of the polymerase chain reaction assay in noninvasive respiratory samples for diagnosis of community-acquired pneumonia. Am J Respir Crit Care Med, 159, 1868–1873.PubMedGoogle Scholar
  163. Mera, R.M., Miller, L.A., Daniels, J.J., Weil, J.G. and White, A.R., (2005), Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States over a 10-year period: Alexander Project. Diagn Microbiol Infect Dis, 51, 195–200.PubMedGoogle Scholar
  164. Metlay, J.P., Hofmann, J., Cetron, M.S., Fine, M.J., Farley, M.M., Whitney, C. and Breiman, R.F., (2000), Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis, 30, 520–528.PubMedGoogle Scholar
  165. Mills, G.D., Oehley, M.R. and Arrol, B., (2005), Effectiveness of beta-lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. BMJ, 330, 456.PubMedGoogle Scholar
  166. Moellering, R.C., (2003), Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med, 138, 135–142.PubMedGoogle Scholar
  167. Montanari, M.P., Mingoia, M., Giovanetti, E. and Varaldo, P.E., (2001), Differentiation of resistance phenotypes among erythromycin-resistant pneumococci. J Clin Microbiol, 39, 9 1311–1315.PubMedGoogle Scholar
  168. Moore, H.F. and Chesney, A.M., (1917), A study of ethylhydrocupreine (optochin) in the treatment of acute lobar pneumonia. Arch Intern Med, 19, 611–613.Google Scholar
  169. Moreno, S., Garcia-Leoni, M.E., Cercenado, E., Diaz, M.D., Bernaldo de Quiros, J.C. and Bouza, E., (1995), Infections caused by erythromycin-resistant Streptococcus pneumoniae: incidence, risk factors, and response to therapy in a prospective study. Clin Infect Dis, 20, 1195–1200.PubMedGoogle Scholar
  170. Mukhtar, T.A., Koteva, K.P., Hughes, D.W. and Wright, G.D., (2001), Vgb from Staphylococcus aureus inactivates streptogramin B antibiotics by an elimination mechanism not hydrolysis. Biochemestry , 40, 8877–8886.Google Scholar
  171. Muñoz, R. and De La Campa, A.G., (1996), ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob Agents Chemother, 40, 2252–2257.PubMedGoogle Scholar
  172. Musher, D.M., (2000), Streptococcus pneumoniae. In L. Mandell, J.E. Bennet and R. Dolin, editors, Principles and Practice of Infections Diseases , 5th edition. Philadelphia, Churchill Livingstone, pp. 2128–2142.Google Scholar
  173. Musher, D.M., Bartlett, J.G. and Doern, G.V., (2001), A fresh look at the definition of susceptibility of Streptococcus pneumoniae to beta-lactam antibiotics. Arch Intern Med, 161, 2538–2544.PubMedGoogle Scholar
  174. Musher, D.M., Dowell, M.E., Shortridge, V.D., Flamm, R.K., Jorgensen, J.H., Le Magueres, P. and Krause, K.L., (2002), Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N Engl J Med, 346, 630–631.PubMedGoogle Scholar
  175. Mutnick, A.H., Enne, V. and Jones, R.N., (2003), Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program. Ann Pharmacother, 37, 769–774.PubMedGoogle Scholar
  176. National Committee for Clinical Laboratory Standards (1999) Performance Standards for Antimicrobial Susceptibility Testing: Ninth Informational Supplement, M100-S9. National Committee for Clinical Laboratory Standards, Wayne, PA, 2000.Google Scholar
  177. National Committee for Clinical Laboratory Standards (2000) Performance Standards for Antimicrobial Susceptibility Testing: Tenth Informational Supplement, M100-S10. National Committee for Clinical Laboratory Standards, Wayne, PA, 2000.Google Scholar
  178. National Committee for Clinical Laboratory Standards (2002) Performance Standards for Antimicrobial Susceptibility Testing: Twelfth Informational Supplement. Document M100-S12. National Committee for Clinical Laboratory Standards, Wayne, PA, 2002.Google Scholar
  179. National Committee for Clinical Laboratory Standards. (1997). Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically, 4th edition. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, PA.Google Scholar
  180. Nava, J.M., Bella, F., Garau, J., Lite, J., Morera, M.A., Marti, C., Fontanals, D., Font, B., Pineda, V., Uriz, S., (1994), Predictive factors for invasive disease due to penicillin-resistant Streptococcus pneumoniae: a population-based study. Clin Infect Dis, 19, 884–890.PubMedGoogle Scholar
  181. Niederman, M.S., (2001), Impact of antibiotic resistance on clinical outcomes and the cost of care. Crit Care Med, 29, N114—N120.PubMedGoogle Scholar
  182. Novak, R., Henriques, B., Charpentier, E., Normark, S. and Tuomanen, E., (1999), Emergence of vancomycin tolerance in Streptococcus pneumoniae. Nature, 399, 590–593.PubMedGoogle Scholar
  183. Nuorti, J.P., Butler, J.C., Crutcher, J.M., Guevara, R., Welch, D., Holder, P. and Elliott, J.A., (1998), An outbreak of multidrug-resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents. N Engl J Med, 338, 1861–1868.PubMedGoogle Scholar
  184. Pallares, R., Fenoll, A. and Linares, J., (2003), The epidemiology of antibiotic resistance in Streptococcus pneumoniae and the clinical relevance of resistance to cephalosporins, macrolides and quinolones. Int J Antimicrob Agents, 22 (Suppl. 1), S15–S24; discussion S25–S16.PubMedGoogle Scholar
  185. Pallares, R., Gudiol, F., Linares, J., Ariza, J., Rufi, G., Murgui, L., Dorca, J. and Viladrich, P.F., (1987), Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci. N Engl J Med, 317, 18–22.PubMedGoogle Scholar
  186. Pallares, R., Linares, J., Vadillo, M., Cabellos, C., Manresa, F., Viladrich, P.F., Martin, R. and Gudiol, F., (1995), Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med, 333, 474–480.PubMedGoogle Scholar
  187. Pan, X.S., Ambler, J., Mehtar, S. and Fisher, L.M., (1996), Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob Agents Chemother, 40, 2321–2326.PubMedGoogle Scholar
  188. Pasteur, L., (1881), Note sur la maladie nouvelle provoquéé par la salive d’un enfant mort de la rage. Bul Acad Méd (Paris), [Series 2].Google Scholar
  189. Patel, R., Piper, K., Cockerill, F.R., 3rd, Steckelberg, J.M. and Yousten, A.A., (2000), The biopesticide Paenibacillus popilliae has a vancomycin resistance gene cluster homologous to the enterococcal VanA vancomycin resistance gene cluster. Antimicrob Agents Chemother, 44, 705–709.PubMedGoogle Scholar
  190. Perez-Trallero, E., Fernandez-Mazarrasa, C., Garcia-Rey, C., Bouza, E., Aguilar, L., Garcia-de-Lomas, J. and Baquero, F., (2001), Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: results of a 1-year (1998–1999) multicenter surveillance study in Spain. Antimicrob Agents Chemother, 45, 3334–3340.PubMedGoogle Scholar
  191. Perez-Trallero, E., Garcia-de-la-Fuente, C., Garcia-Rey, C., Baquero, F., Aguilar, L., Dal-Re, R. and Garcia-de-Lomas, J., (2005), Geographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain. Antimicrob Agents Chemother, 49, 1965–1972.PubMedGoogle Scholar
  192. Pestova, E., Beyer, R., Cianciotto, N.P., Noskin, G.A. and Peterson, L.R., (1999), Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones. Antimicrob Agents Chemother, 43, 2000–2004.PubMedGoogle Scholar
  193. Piddock, L.J., (1999), Mechanisms of fluoroquinolone resistance: an update 1994–1998. Drugs, 58 (Suppl. 2), 11–18.PubMedGoogle Scholar
  194. Pons, J.L., Mandement, M.N., Martin, E., Lemort, C., Nouvellon, M., Mallet, E., Lemelnad, J.F., (1996), Clonal and temporal patterns of nasopharyngeal penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae strains in children attending a day care center. J Clin Microbiol, 34, 3218–3222.PubMedGoogle Scholar
  195. Poole, M.D., (1995), Otitis media complications and treatment failures: implications of pneumococcal resistance. Pediatr Infect Dis J, 14, S23–S26.PubMedGoogle Scholar
  196. Portillo, A., Ruiz-Larrea, F., Zarazaga, M., Alonso, A., Martinez, J.L. and Torres, C., (2000), Macrolide resistance genes in Enterococcus spp. Antimicrob Agents Chemother, 44, 967–971.PubMedGoogle Scholar
  197. Pottumarthy, S., Fritsche, T.R. and Jones, R.N., (2005), Comparative activity of oral and parenteral cephalosporins tested against multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1997–2003). Diagn Microbiol Infect Dis, 51, 147–150.PubMedGoogle Scholar
  198. Powers JH., (2004), Antimicrobial drug development – the past, the present, and the future. Clin Microbiol Infect , 10 (Suppl. 4), 23–31.PubMedGoogle Scholar
  199. Prystowsky, J., Siddiqui, F., Chosay, J., Shinabarger, D.L., Millichap, J., Peterson, L.R. and Noskin, G.A., (2001), Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob Agents Chemother, 45, 2154–2156.PubMedGoogle Scholar
  200. Raad, II., Hanna, H.A., Hachem, R.Y., Dvorak, T., Arbuckle, R.B., Chaiban, G. and Rice, L.B., (2004), Clinical-use-associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid: a comparison with quinupristin-dalfopristin. Antimicrob Agents Chemother, 48, 3583–3585.Google Scholar
  201. Rosato, A., Vicarini, H., Bonnefoy, A., Chantot, J.F. and Leclercq, R., (1998), A new ketolide, HMR 3004, active against streptococci inducibly resistant to erythromycin. Antimicrob Agents Chemother, 42, 1392–1396.PubMedGoogle Scholar
  202. Ross, J.J., Worthington, M.G. and Gorbach, S.L., (2002), Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med, 347, 65–67; author reply 65–67.PubMedGoogle Scholar
  203. Ruiz, M., Ewig, S., Torres, A., Arancibia, F., Marco, F., Mensa, J., Sanchez, M. and Martinez, J.A., (1999), Severe community-acquired pneumonia. Risk factors and follow-up epidemiology. Am J Respir Crit Care Med, 160, 923–929.PubMedGoogle Scholar
  204. Sahm, D.F., Karlowsky, J.K. and Kelly, L.J., (2001), Need for annual surveillance of antimicrobial resistance in the United States: 2 year longitudinal analysis. Antimicrob Agents Chemother, 45, 1037–1042.PubMedGoogle Scholar
  205. Sanchez, F., Mensa, J., Martinez, J.A., Garcia, E., Marco, F., Gonzalez, J., Marcos, M.A., Soriano, A. and Torres, A., (2003), Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia? Clin Infect Dis, 36, 1239–1245.PubMedGoogle Scholar
  206. Schmidt, L.H., (1943), Development of resistance to penicillin by pneumococci. Proc Soc Exp Biol Med, 53, 353–357.Google Scholar
  207. Schmitz, F.J., Verhoef, J., Milatovic, D. and Fluit, A.C., (2001), Treatment options for Streptococcus pneumoniae strains resistant to macrolides, tetracycline, quinolones, or trimethoprim/sulfamethoxazole. Eur J Clin Microbiol Infect Dis, 20, 827–829.PubMedGoogle Scholar
  208. Schrag, S.J., Beall, B. and Dowell, S.F., (2000), Limiting the spread of resistant pneumococci: biological and epidemiologic evidence for the effectiveness of alternative interventions. Clin Microbiol Rev, 13, 588–601.PubMedGoogle Scholar
  209. Schrag, S.J., McGee, I., Whitney, C.G.,Beall, B., Craig, A.S., Choate, M.E., Jorgensen, J.H., Facklam, R.R., Klugman, K.P., and The Active Bacterial Core Surveillance Team, (2004), Emergence of Streptococcus pneumoniae with very-high-level resistance to penicillin. Antimicrob Agents Chemother, 48, 3016–3023.PubMedGoogle Scholar
  210. Schuchat, A., Robinson, K., Wenger, J.D., Harrison, L.H., Farley, M., Reingold, A.L., Lefkowitz, L. and Perkins, B.A., (1997), Bacterial meningitis in the United States in 1995. Active Surveillance Team. N Engl J Med, 337, 970–976.PubMedGoogle Scholar
  211. Shefet, D., Robenshtok, E., Paul, M. and Leibovici, L., (2005), Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized controlled trials. Arch Intern Med, 165, 1992–2000.PubMedGoogle Scholar
  212. Silverman, J.A., Oliver, N., Andrew, T. and Tongchuani, L., (2001), Resistance studies with daptomycin. Antimicrob Agents Chemother , 45, 1799–1802.PubMedGoogle Scholar
  213. Sinclair, A., Arnold, C. and Woodford, N., (2003), Rapid detection and estimation by pyrosequencing of 23S rRNA genes with a single nucleotide polymorphism conferring linezolid resistance in Enterococci. Antimicrob Agents Chemother, 47, 3620–3622.PubMedGoogle Scholar
  214. Singh, K.V., Weinstock, G.M. and Murray, B.E., (2002), An Enterococcus faecalis ABC homologue (Lsa) is required for the resistance of this species to clindamycin and quinupristin-dalfopristin. Antimicrob Agents Chemother, 46, 1845–1850.PubMedGoogle Scholar
  215. Sloas, M.M., Barrett, F.F., Chesney, P.J., English, B.K., Hill, B.C., Tenover, F.C. and Leggiadro, R.J., (1992), Cephalosporin treatment failure in penicillin- and cephalosporin-resistant Streptococcus pneumoniae meningitis. Pediatr Infect Dis J, 11, 662–666.PubMedGoogle Scholar
  216. Smith, H.J., Walters, M., Hisanaga, T., Zhanel, G.G. and Hoban, D.J., (2004a), Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates. Antimicrob Agents Chemother, 48, 3954–3958.Google Scholar
  217. Smith, H.J., Noreddin, A.M., Siemens, C.G., Schurek, H., Greisman, J., Hoban, C., Homan, D. and Zhanel, G., (2004b), Designing fluoroquinolone breakpoints for Streptococcus pneumoniae by using genetics instead of pharmacokinetics-pharmacodynamics. Antimicrob Agents Chemother, 48, 3630–3635.Google Scholar
  218. Spellberg, B., Powers, J.H., Brass, E.P., Miller, L.G. and Edwards, J.E., Jr., (2004), Trends in antimicrobial drug development: implications for the future. Clin Infect Dis, 38, 1279–1286.PubMedGoogle Scholar
  219. Stahl, J.E., Barza, M., DesJardin, J., Martin, R. and Eckman, M.H., (1999), Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch Intern Med, 159, 2576–2580.PubMedGoogle Scholar
  220. Sternberg, G., (1881), A fatal form of septicaemia in the rabbit, produced by the subcutaneous injection of human saliva. Ann resp Nath Board Health, 3, 87–108.Google Scholar
  221. Stevens, D.L., Dotter, B. and Madaras-Kelly, K., (2004), A review of linezolid: the first oxazolidinone antibiotic. Expert Rev Anti Infect Ther, 2, 51–59.PubMedGoogle Scholar
  222. Sutcliffe, J., Tait-Kamradt, A. and Wondrack, L., (1996), Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother, 40, 1817–1824.PubMedGoogle Scholar
  223. Tankovic, J., Lascols, C., Sculo, Q., Petit, J.C. and Soussy, C.J., (2003), Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori. Antimicrob Agents Chemother, 47, 3942–3944.PubMedGoogle Scholar
  224. Tenover, F.C., Weigel, L.M., Appelbaum, P.C., McDougal, L.K., Chaitram, J., McAllister, S., Clark, N., Killgore, G., O’Hara, C.M., Jevitt, L., Patel, J.B. and Bozdogan, B., (2004), Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob Agents Chemother, 48, 275–280.PubMedGoogle Scholar
  225. Thorne, G.M. & Alder, J., (2002), Daptomycin: a novel lipopeptide antibiotic. Clin Microbiol News L, 24, 33–40.Google Scholar
  226. Tillotson, G., Zhao, X. & Drlica, K., (2001), Fluoroquinolones as pneumococcal therapy: closing the barn door before the horse escapes. Lancet Infect Dis, 1, 145–146.PubMedGoogle Scholar
  227. Tillotson, G. and Watson, S., (2001), Antimicrobial resistence mechanisms: what’s hot and what’s not in respiratory pathogens. Semin Respir Infect, 16, 155–168.PubMedGoogle Scholar
  228. Tomasz A., (1999), New faces of an old pathogen: emergence and spread of multidrug-resistant Streptococcus pneumoniae. Am J Med, 107 (Suppl. 1A), 55S–62S.Google Scholar
  229. Turett, G.S., Blum, S., Fazal, B.A., Justman, J.E. and Telzak, E.E., (1999), Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence. Clin Infect Dis, 29, 321–327.PubMedGoogle Scholar
  230. Urban, C., Rahman, N., Zhao, X., Mariano, N., Segal-Maurer, S., Drlica, K. and Rahal, J.J., (2001), Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy. J Infect Dis, 184, 794–798.PubMedGoogle Scholar
  231. Uttley, A.H., Collins, C.H., Naidoo, J. and George, R.C., (1988), Vancomycin-resistant enterococci. Lancet, 1, 57–58.PubMedGoogle Scholar
  232. Van Bambeke, F., Van Laethem, Y., Courvalin P. and Tulkens PM., (2004), Glycopeptide antibiotics from conventional molecules to new derivatives. Drugs, 64, 913–936.PubMedGoogle Scholar
  233. Vanderkooi, O.G., Low D.E., Green, K. Powis, J.P. and McGeer, A., (2005), Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis, 40, 1288–97PubMedGoogle Scholar
  234. Vannufel, P. and Cocito, C., (1996), Mechanism of action of streptogramins and macrolides. Drugs, 51 (Suppl. 1), 20–30.Google Scholar
  235. Verhaegen, J. and Verbist, L., (1999), In-vitro activities of 16 non-beta-lactam antibiotics against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae. J Antimicrob Chemother, 43, 563–567.PubMedGoogle Scholar
  236. Waterer, G.W., Somes, G.W. and Wunderink, R.G., (2001), Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med, 161, 1837–1842.PubMedGoogle Scholar
  237. Waterer, G.W., Wunderink, R.G. and Jones, C.B., (2000), Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy. Chest, 118, 1839–1840.PubMedGoogle Scholar
  238. Weiss, K. and Tillotson, G., (2005), The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia. Chest, 128, 940–946.PubMedGoogle Scholar
  239. Whitney, C.G., Farley, M.M., Hadler, J., Harrison, L.H., Lexau, C., Reingold, A., Lefkowitz, L., Cieslak, P.R., Cetron, M., Zell, E.R., Jorgensen, J.H. and Schuchat, A., (2000), Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med, 343, 1917–1924.PubMedGoogle Scholar
  240. Woodford, N., (2005), Biological counterstrike: antibiotic resistance mechanisms of Gram-positive cocci. Clin Microbiol Infect, 11(Suppl. 3), 2–21.PubMedGoogle Scholar
  241. Woods, D., (1962), The biochemical mode of sulphonamide drug. J Gen Microbiol, 29, 687–702.Google Scholar
  242. Wright, G. D., (2003), Mechanisms of resistance to antibiotics. Curr Opin Chem Biol, 7, 563–569.PubMedGoogle Scholar
  243. Yu, V.L., Chiou, C.C., Feldman, C., Ortqvist, A., Rello, J., Morris, A.J., Baddour, L.M., Luna, C.M., D.R., S., Ip, M., Ko, W.C., M.B.F., C., Andremont, A. and Klugman, H.P., (2003), An international prospective study of pneumococcal bacteremia: Correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis, 37, 230–237.PubMedGoogle Scholar
  244. Zhanel, G.G., Hoban, D.J. and Chan, C.K., (2002), Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med, 347, 65–67; author reply 65–67.PubMedGoogle Scholar
  245. Zhanel, G.G., Palatnich, L., Nichol, K.A., Bellyou, T., Low, D.E. and Hoban, D.J., (2003), Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002, Antimicrob Agents Chemother, 47, 1867–1874.PubMedGoogle Scholar
  246. Zhao, X., and Drlica, K., (2001), Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis, 33, S147–S156.PubMedGoogle Scholar
  247. Zhao, X. and Drlica, K., (2002), Restricting the selection of antibiotic-resistant mutants: measurement and potenial uses of the mutant selection window. J Inf Dis, 185, 561–565.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Javier Aspa Marco
  • Olga Rajas Naranjo
  • Felipe Rodriguez de Castro
  • Buenaventura Buendía
  • Jesús Sanz Sanz

There are no affiliations available

Personalised recommendations